SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brander who wrote (2405)2/18/1998 11:01:00 PM
From: Bradpalm1  Read Replies (1) of 7041
 
<< A 50% drop out rate is not good, but many initial trials do have high drop out rates.>>

Brad, we're talking about Phase III trials here --- NOT initial Phase I or II trials. "not good" is a profound understatement for a drug presumably vying for 'fast-track' NDA status if submitted within the next two weeks (approval of Pfizer's Viagra by the FDA is apparently imminent).

Sounds like apomorphine has a better chance of a NDA submission and FDA approval than Vasomax.

Bradpalm1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News